What is Poly Group?
Poly Group LLC is the exclusive licensor of Nouvex®, an innovative antimicrobial additive engineered to bolster cleanliness and actively combat bacteria and viruses. The company provides advanced antimicrobial solutions across a diverse range of sectors, including consumer products, commercial applications, textiles, building materials, and healthcare. The Nouvex technology, originally developed at Purdue University, delivers potent antimicrobial, antiviral, and antifungal properties while proactively addressing concerns related to bacterial resistance and toxicity. Poly Group is strategically positioned to lead the global market in antimicrobial protection, aiming to offer superior alternatives to conventional solutions.
How much funding has Poly Group raised?
Poly Group has raised a total of $634K across 1 funding round:
Private Equity
$634K
Private Equity (2015): $634K, investors not publicly disclosed
What's next for Poly Group?
With a substantial enterprise-level funding context and a recent major strategic investment, Poly Group is poised for accelerated growth and market penetration. The company's focus on advanced antimicrobial technology, particularly Nouvex, positions it to capitalize on increasing global demand for enhanced hygiene and safety solutions. Future endeavors will likely involve scaling production, expanding market reach into new sectors, and potentially further research and development to maintain its competitive edge against emerging threats and existing alternatives. This strategic financing is expected to fuel innovation and solidify Poly Group's leadership in antimicrobial protection.
See full Poly Group company page
